MetrioPharm Patents: Developments in all key markets
MetrioPharm AG was able to make further progress with regard to the patent protecti on of MP1032 in the fi rst months of 2014. Aft er previously obtaining the patent grant in Switzerland, the European Patent Offi ce has now declared its intenti on to grant a European patent (Notificati on 71 (3) EPÜ). Thereby MP1032 is now fully protected in one of our most criti cal markets.
An important milestone towards obtaining a fi rst patent grant was also achieved in the US market. The United States Patent Offi ce declared all major claims and the most important minor claims to be allowable. Therefore, a granti ng in the US market is quite likely within the current year.
All patents would extend unti l 2031 - therefore, MetrioPharm AG holds the exclusive right of uti lizati on for another 17 years. Such a long remaining patent life at this advanced stage of drug development is a rare occurrence in the pharmaceuti cal industry and poses a signifi cant advantage for future licensing and marketi ng.
Investment round C
In conjunction with MetrioPharm AG's current capital increase, the company is off ering registered shares with a nominal value of CHF 0.20 for the price of CHF 0.60. The total amount of investment round C is CHF 6.72 million which corresponds to 11.2 million new shares. The subscripti on period ends on the 9th of May 2014. Investment round C will fund all expected development costs as well MetrioPharm AG has achieved further milestones in solidifying its intellectual property! as the monthly burn rate unti l the completi on of clinical phase I. In this context MetrioPharm AG recently presented the latest developments to potenti al investors in Zurich, Geneva, and London. At this ti me about two thirds of the new shares are already subscribed. Team MetrioPharm AG's R&D staff is growing further. Starti ng on the 17th of March Dr. Jan Weber supports our team and the development of MP1000. Copyright © 2014 MetrioPharm AG, All rights reserved. MetrioPharm AG has achieved further milestones in solidifying its intellectual property!
MetrioPharm AG’s R&D staff is growing further. Starting on the 17th of March Dr. Jan Weber supports our team and the development of MP1000.